Rosen Law Firm Urges Aardvark Therapeutics Investors to Act Before October 13 Deadline

Rosen Law Firm, an international investor rights law firm, has alerted purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD) securities to an important lead plaintiff deadline of October 13, 2026.

The lawsuit concerns statements made in connection with the company's initial public offering (IPO) on February 13, 2025, and securities purchased between February 13, 2025, and May 14, 2026. The firm alleges that defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business, operations, and prospects.

Specifically, the complaint claims that defendants failed to disclose that AARD-101 was less safe than represented and that its clinical, regulatory, and commercial prospects were overstated. Investors who purchased Aardvark securities during the class period may be entitled to compensation without paying out-of-pocket expenses through a contingency fee arrangement.

Potential lead plaintiffs must move the court by October 13, 2026. A lead plaintiff is a representative party acting on behalf of other class members. No class has yet been certified, and investors may retain counsel of their choice or remain absent class members.